Key Points
- Rein Therapeutics insider James Brian Windsor bought 25,000 shares on April 30 at $1.00 each, a $25,000 purchase that boosted his ownership to 27,046 shares.
- The stock recently traded at $1.16, near its 52-week low of $1.00 and well below its 52-week high of $2.40, giving the company a market cap of about $32.5 million.
- Wall Street sentiment is mixed but cautious: the stock has an average Hold rating and a $8.00 price target, while institutional ownership remains high at 90.89%.
Rein Therapeutics Inc. (NASDAQ:RNTX - Get Free Report) insider James Brian Windsor purchased 25,000 shares of the stock in a transaction that occurred on Thursday, April 30th. The shares were acquired at an average cost of $1.00 per share, with a total value of $25,000.00. Following the completion of the transaction, the insider owned 27,046 shares in the company, valued at $27,046. This trade represents a 1,221.90% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Rein Therapeutics Price Performance
Shares of NASDAQ RNTX opened at $1.16 on Thursday. Rein Therapeutics Inc. has a 1 year low of $1.00 and a 1 year high of $2.40. The firm has a 50-day moving average of $1.38 and a 200 day moving average of $1.34. The stock has a market cap of $32.53 million, a P/E ratio of -0.59 and a beta of 1.42.
Hedge Funds Weigh In On Rein Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of RNTX. Susquehanna International Group LLP bought a new position in shares of Rein Therapeutics during the third quarter valued at $35,000. HRT Financial LP bought a new stake in Rein Therapeutics in the 4th quarter worth about $38,000. Chicago Partners Investment Group LLC increased its holdings in Rein Therapeutics by 32.2% in the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company's stock worth $53,000 after buying an additional 10,000 shares in the last quarter. Northwestern Mutual Wealth Management Co. bought a new stake in Rein Therapeutics in the 2nd quarter worth about $68,000. Finally, Jane Street Group LLC bought a new stake in Rein Therapeutics in the 4th quarter worth about $72,000. 90.89% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on the company. Weiss Ratings restated a "sell (e+)" rating on shares of Rein Therapeutics in a report on Thursday, January 22nd. downgraded Rein Therapeutics from a "buy" rating to a "hold" rating in a report on Wednesday, January 21st. Finally, Citigroup downgraded Rein Therapeutics to a "hold" rating in a report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $8.00.
Check Out Our Latest Report on RNTX
About Rein Therapeutics
(
Get Free Report)
Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company's core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.
The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
